Active Ingredient History
Lovastatin acid is an active metabolite of hypolipidemic drug Lovastatin. Lovastatin acid inhibits HMG-CoA reductase. This enzyme catalyzes the conversion of HMG-CoA to mevalonate, which is an early and rate limiting step in the biosynthesis of cholesterol. Lovastatin has been shown to reduce both normal and elevated low-density lipoprotein cholesterol (LDL-C). Lovastatin in approved for prevention of cardiovascular events and hypercholesterolemia. Off-label use of lovastatin includes treatmetn of diabetic dyslipidemia, familial dysbetalipoproteinemia, familial combined hyperlipidemia, or nephrotic hyperlipidemia. Lovastatin was tested in clinical trials agains radioation injury during therapy of prostate cancer. NCATS
Drug Pricing (per unit)
Note: This drug pricing data is preliminary, incomplete, and may contain errors.
Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
---|
Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
---|
Alveolar Bone Loss (Phase 2/Phase 3)
Alzheimer Disease (Phase 4)
Arthritis, Rheumatoid (Phase 2)
Asthma (Phase 1/Phase 2)
Atherosclerosis (Phase 4)
Blood Platelets (Phase 2)
Breast Neoplasms (Phase 2)
Cardiovascular Diseases (Phase 3)
Carotid Stenosis (Phase 2)
Cerebrovascular Disorders (Phase 2)
Cognition Disorders (Phase 2)
Coronary Artery Disease (Phase 3)
Coronary Disease (Phase 3)
Disability Evaluation (Phase 2)
Drug Interactions (Phase 1)
Dyslipidemias (Phase 4)
Fragile X Syndrome (Phase 4)
Genetic Diseases, Inborn (Phase 4)
Healthy Volunteers (Phase 4)
Heart Diseases (Phase 3)
HIV Seropositivity (Phase 2)
Hyperlipidemias (Phase 4)
Ichthyosis (Phase 2)
Inflammation (Phase 4)
Intermittent Claudication (Phase 3)
Intracranial Arteriosclerosis (Phase 2)
Intracranial Arteriovenous Malformations (Phase 2)
Jaundice (Phase 2)
Keratosis, Actinic (Phase 1/Phase 2)
Learning Disabilities (Phase 2)
Leukemia, Myeloid, Acute (Phase 1/Phase 2)
Lipid Metabolism Disorders (Phase 1)
Melanoma (Phase 2)
Musculoskeletal Abnormalities (Phase 2)
Myocardial Ischemia (Phase 3)
Neoplasms (Phase 1/Phase 2)
Neurofibroma (Phase 2)
Neurofibromatosis 1 (Phase 2)
Neuronal Plasticity (Phase 2)
Ovarian Neoplasms (Phase 2)
Parkinson Disease (Phase 2)
Pediatrics (Phase 2)
Peripheral Vascular Diseases (Phase 3)
Pneumonia (Early Phase 1)
Precancerous Conditions (Phase 2)
Prostatic Neoplasms (Phase 2)
Pulmonary Disease, Chronic Obstructive (Phase 2)
Rett Syndrome (Phase 2)
Rhabdomyolysis (Phase 2)
Smith-Lemli-Opitz Syndrome (Phase 2)
Stroke (Phase 2)
Vascular Diseases (Phase 2)
Xanthomatosis, Cerebrotendinous (Phase 2)
Trial | Phase | Start Date | Organizations | Indications |
---|
Feedback
Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).
Report issue